AngioDynamics Prepares for Q1 Results Amid Analyst Optimism

Author: Owen Jenkins Updated: 10-01-2025 10:12 AM

AngioDynamics Gears Up for First Quarter Earnings Release

AngioDynamics, Inc. (NASDAQ: ANGO) is set to unveil its earnings results for the first quarter soon, sparking significant anticipation among investors and analysts alike. The earnings announcement is expected before the market opens on an upcoming Thursday, marking a pivotal moment for the company.

Analyst Expectations for the Earnings Report

Experts have projected that the Latham-based company will report a quarterly loss of 12 cents per share. This is slightly worse than the loss of 11 cents per share reported during the same period last year. However, in terms of revenue, AngioDynamics is expected to report a total of $72.69 million for this quarter, reflecting a growth from $67.49 million compared to the prior year.

Recent Performance and Forward Guidance

In a preceding report published in July, AngioDynamics shared encouraging financial outcomes for their fourth quarter, surpassing expectations and even issuing a revenue guidance for the fiscal year that suggested potential growth beyond analyst forecasts.

Stock Movement and Market Reaction

In response to these developments, shares of AngioDynamics experienced a positive uptick, rising by 4% to close at $11.17 on one recent trading day. This upward trend highlights the market's confidence in the company’s ability to navigate its financial challenges and capitalize on growth opportunities.

Insights from Analysts on ANGO

Market analysts have been closely monitoring AngioDynamics and have shared their ratings and outlook. Recently, Yi Chen of HC Wainwright & Co. reaffirmed a Buy rating for ANGO with a price target of $16, reflecting a solid confidence level with an accuracy rate of 64%. In a similar vein, William Plovanic of Canaccord Genuity maintained a Buy rating and updated the price target from $15 to $17, showcasing a positive upward shift in expectation.

Analyst Ratings and Stock Buying Considerations

For those considering investing in AngioDynamics stock, the consistent Buy ratings from analysts may provide a reassuring sign. It’s crucial to weigh these recommendations alongside other market factors to make informed investment choices.

Looking Ahead: What’s Next for AngioDynamics?

As AngioDynamics approaches its earnings report, many market participants are keenly awaiting the results which could further solidify or challenge current analyst projections. The company's ability to meet or exceed these expectations will play a significant role in shaping its stock performance in the near future.

Frequently Asked Questions

What is the expected earnings loss for AngioDynamics?

Analysts expect AngioDynamics to report a quarterly loss of 12 cents per share for the upcoming earnings report.

What revenue growth does AngioDynamics project for the quarter?

The company expects to report quarterly revenue of $72.69 million, an increase from $67.49 million from the same quarter last year.

How have recent market trends affected AngioDynamics' stock?

Following positive fourth-quarter results and analyst endorsements, AngioDynamics' stock rose by 4% to close at $11.17 one trading day.

What ratings have analysts given AngioDynamics stock?

Analysts like Yi Chen and William Plovanic have reiterated Buy ratings, with price targets ranging from $16 to $17, indicating positive market sentiment.

Why is the upcoming earnings report significant?

The upcoming earnings report will be crucial for evaluating AngioDynamics' financial health and growth potential, which could influence investor decisions moving forward.

About The Author

Hi there I'm 38-year-old author and financial consultant Owen Jenkins. Having worked in the financial sector for more than ten years, I am well-versed in the subtleties and complexity that mold our financial environment. Following a degree in finance, I worked in a number of financial institutions honing my abilities in market analysis, financial planning, and investment strategies.

My love is teaching others about investing and personal finance. My goal in writing many books and articles has been to demystify financial ideas and give readers the information they need to make wise financial decisions. I write with a direct, useful style that emphasizes doable suggestions for daily living.

Along with writing, I lead webinars and seminars where I impart knowledge on how to successfully negotiate the financial world. I also write for financial journals and show up as a guest expert on financial news programs a lot. Whether they are new to investing or want to improve their approach, my mission is to enable people to take charge of their financial futures.

Beyond work, I like to hike, play the guitar, and spend time with my family. I think that balance is crucial and want to encourage people to strike a balance between their financial aspirations and their hobbies. I want to help people succeed and achieve financial security through my work, so having a good influence.

Contact Owen Jenkins privately here. Or send an email with ATTN: Owen Jenkins as the subject to contact@investorshangout.com.

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.